Microbot Medical With The Addition Of Memorial Sloan Kettering Cancer Center Gets IRB Approval And Completes Enrollment Of Clinical Sites In Its Pivotal Human Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Microbot Medical Inc. (NASDAQ: MBOT) has received IRB approval and signed a clinical trial agreement with Memorial Sloan Kettering Cancer Center for its LIBERTY® Endovascular Robotic Surgical System. The trial results are expected to support future FDA marketing submissions and commercialization.
July 18, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Microbot Medical Inc. has received IRB approval and signed a clinical trial agreement with Memorial Sloan Kettering Cancer Center for its LIBERTY® Endovascular Robotic Surgical System. The trial results are expected to support future FDA marketing submissions and commercialization.
The IRB approval and partnership with a prestigious institution like Memorial Sloan Kettering Cancer Center are significant milestones for Microbot Medical. These developments increase the likelihood of successful clinical trials, FDA approval, and subsequent commercialization, which are positive indicators for the company's stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100